Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.10.7.13240DOI Listing

Publication Analysis

Top Keywords

angiogenic profile
4
profile colorectal
4
colorectal cancer
4
cancer patients
4
patients open
4
open laparoscopic
4
laparoscopic colectomy
4
angiogenic
1
colorectal
1
cancer
1

Similar Publications

Hemorrhagic stroke is a known complication of glioma, yet the underlying mechanisms remain poorly understood. This study aims to investigate key biomarkers of glioma-related hemorrhage to provide insights into glioma molecular therapies. Data were obtained from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) databases to analyze differentially expressed genes (DEGs) in glioma by contrasting glioblastoma (GBM) with low-grade gliomas (LGGs).

View Article and Find Full Text PDF

Network Pharmacology Unveils Multi-Systemic Intervention of Panax notoginseng in Osteoporosis via Key Genes and Signaling Pathways.

Endocr Metab Immune Disord Drug Targets

January 2025

Department of Orthopaedics, Xiaolan People's Hospital of Zhongshan, Zhongshan, Guangdong Province, People's Republic of China.

Background: Panax notoginseng (Burk.) F. H.

View Article and Find Full Text PDF

Postoperative concurrent chemoradiotherapy plus apatinib for patients with high-grade glioma: a retrospective cohort study.

Chin Clin Oncol

December 2024

Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team (Dongfang Hospital), Xiamen University, Fuzhou, China.

Background: Radiotherapy plus temozolomide followed by adjuvant temozolomide was the standard treatment for high-grade gliomas. This study aimed to explore the effectiveness and safety of the addition of apatinib in patients with high-grade gliomas after surgery.

Methods: In this retrospective cohort study, patients with high-grade glioma [World Health Organization (WHO) grade III or IV] treated with apatinib and concurrent chemoradiotherapy (cCRT) after surgery from October 2017 to February 2021 were reviewed.

View Article and Find Full Text PDF

The overview of lactylation in the placenta of preeclampsia.

Placenta

January 2025

Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen, China; Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecological Diseases, Shenzhen, China. Electronic address:

Background: Preeclampsia is a major challenge for obstetricians due to its severe impacts on maternal and fetal health. Lysine lactylation (Kla) derived from lactate is a novel type of post-translational modification which has been confirmed to affect the malignant progression of diseases as an epigenetic modifier. However, the systemic lactylome profiling of preeclampsia is still unclear.

View Article and Find Full Text PDF

NOTCH and IGF1 signaling systems are involved in the effects exerted by anthelminthic treatment of heifers on the bovine mammary gland.

Vet Parasitol

January 2025

Centro de Investigaciones Básicas y Aplicadas, Universidad Nacional del Noroeste de la Provincia de Buenos Aires, Junín, Buenos Aires 6000, Argentina; Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires, CITNOBA, UNNOBA - UNSAdA - CONICET, Monteagudo 2772, Pergamino, Buenos Aires 2700, Argentina. Electronic address:

Dairy heifers with gastrointestinal nematodes have reduced growth rates, and delayed age at puberty and milk production onset related to late mammary gland development. IGF1 and Notch signaling systems are important in this process, and an altered profile of serum IGF1 has been associated with the detrimental effect of the nematodes on parenchymal development. In this context, we aimed to study the molecular mechanisms involved in bovine mammary gland development around pre and postpuberty, focusing on proliferative and angiogenic processes that involve the Notch and IGF1 pathways.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!